These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 84457)

  • 21. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 22. [Evaluation of the immunological activity of a vaccine from mutant Salmonella minnesota R 595 on a model of experimental Pseudomonas aeruginosa infection in mice].
    Likhoded VG; Apollonin AV; Gremiakova TA; Artemova EK
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Apr; (4):103-6. PubMed ID: 6408854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A polyvalent Pseudomonas vaccine.
    Sato H; Diena BB
    Rev Can Biol; 1974 Jun; 33(2):93-7. PubMed ID: 4211759
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 25. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas vaccine. 3. Evaluation of a polyvalent vaccine.
    De Fajardo CL; Laborde HF
    J Bacteriol; 1968 May; 95(5):1968-9. PubMed ID: 4967780
    [No Abstract]   [Full Text] [Related]  

  • 28. Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.
    Robinson CM; Kobe BN; Schmitt DM; Phair B; Gilson T; Jung JY; Roberts L; Liao J; Camerlengo C; Chang B; Davis M; Figurski L; Sindeldecker D; Horzempa J
    Bioengineered; 2015; 6(2):82-8. PubMed ID: 25617059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
    Sourek J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.
    Elhosary MA; Bahey-El-Din M; AbdelBary A; El Guink N; Aboushleib HM
    Microb Pathog; 2019 Jun; 131():181-185. PubMed ID: 30978430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.
    Jones RJ
    J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
    Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
    Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
    Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
    Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
    Front Immunol; 2018; 9():1737. PubMed ID: 30093906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.